Effects of Tolperisone on Measures of Drowsiness and Cognitive Function
Status:
Completed
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
A Randomized, 4-Period, Crossover Study to characterize the effects of tolperisone 200 mg and
400 mg (supratherapeutic dose) three times a day (TID) over 3 days of dosing on measures of
simulated driving performance, cognitive function and drowsiness and compared to placebo and
cyclobenzaprine (single-day, residual effect, multiple-day).